Unveiling the pulmonary burden of idiopathic inflammatory myopathies in South Africa
Article Sidebar
Main Article Content
Abstract
-
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Milone M. Diagnosis and management of immune-mediated myopathies. Mayo Clin Proc 2017;92(5):826-837. https://doi.org/10.1016/j.mayocp.2016.12.025
2. Hes T, Wong M, Tikly M, Govind N. Pulmonary manifestations of the idiopathic inflammatory myopathies in a South African population. Afr J Thoracic Crit Care Med 2024;30(3):e1663. https://doi.org/10.7196/AJTCCM.2024.v30i3.1663
3. LongK,DanoffSK.Interstitiallungdiseaseinpolymyositisanddermatomyositis.Clin Chest Med 2019;40(3):561-572. https://doi.org/10.1016/j.ccm.2019.05.004
4. Kiely PD, Chua F. Interstitial lung disease in inflammatory myopathies: Clinical phenotypes and prognosis. Curr Rheumatol Rep 2013;15(9):359. https://doi. org/10.1007/s11926-013-0359-6
5. Cobo-Ibáñez T, López-Longo F-J, Joven B, et al. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin Rheumatol 2019;38(3):803-815. https://doi.org/10.1007/s10067- 018-4353-2
6. Vu TTT, Brown KK, Solomon JJ. Myositis-associated interstitial lung disease. Curr Opin Pulm Med 2023;29(5):427-435. https://doi.org/10.1097/MCP.0000000000001000 7. Chang S, Shin MH, Shin JH, Park MS. Clinical characteristics of anti-Jo-1-positive interstitial lung disease. Eur Respir J 2019;54(Suppl 63):PA5183. https://doi.
org/10.1183/13993003.congress-2019.PA5183
8. Ndamase S, Okpechi I, Carrara H, Black J, Calligaro G, Freercks R. Tuberculosis burden in stage 5 chronic kidney disease patients undergoing dialysis therapy at Livingstone Hospital, Port Elizabeth, South Africa. S Afr Med J 2020;110(5):422-426. https://doi.org/10.7196/SAMJ.2020.v110i5.14035
9. Torre-CisnerosJ,DoblasA,AguadoJM,etal.Tuberculosisaftersolid-organtransplant: Incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009;48(12):1657-1665. https://doi.org/10.1086/599035
10. Yuan Z, Chao S, Xu Y, Niu Y. Chemoprophylaxis for the prevention of tuberculosis in kidney transplant recipients: A systematic review and meta-analysis. Front Pharmacol 2023;14:1022579. https://doi.org/10.3389/fphar.2023.1022579